Maxigen BiotechTPE:1783 -0.51%87 Current Ratio is 3.21 as of Dec. 2025, which is 34% below its 10-year median of 4.86. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$61.08 (Significantly Undervalued). Among 855 Medical Devices & Instruments companies, Maxigen Biotech ranks better than 61.64% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Maxigen Biotech's current ratio for the quarter that ended in Dec. 2025 was 3.21.
Maxigen Biotech has a current ratio of 3.21. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Maxigen Biotech's Current Ratio or its related term are showing as below:
TPE:1783'
s Current Ratio Range Over the Past 10 Years
Min: 1.99 Med: 4.86 Max: 6.91
Current: 3.21
During the past 13 years, Maxigen Biotech's highest Current Ratio was 6.91. The lowest was 1.99. And the median was 4.86.
TPE:1783's Current Ratio is ranked better than 61.64% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 2.49
vs TPE:1783: 3.21
Maxigen Biotech (TPE:1783) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Maxigen Biotech Current Ratio Related Terms
Maxigen Biotech Current Ratio Historical Data
* Premium members only.
The historical data trend for Maxigen Biotech's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1783 vs ISRG, BDX, MDLN: Current Ratio Comparison
For the Medical Instruments & Supplies subindustry, Maxigen Biotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Maxigen Biotech Current Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Maxigen Biotech's Current Ratio distribution charts can be found below:
* The bar in red indicates where Maxigen Biotech's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Maxigen Biotech (TPE:1783) has a Current Ratio of 3.21 as of Dec. 2025. This is 34% below median its historical median of 4.86. Over the past decade, Maxigen Biotech's Current Ratio has ranged from 1.99 to 6.91. According to the industry distribution chart, Maxigen Biotech ranks #328 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 38.4%.
Is Maxigen Biotech's Current Ratio too high?
Maxigen Biotech's current Current Ratio of 3.21 is 34% below median its 10-year median of 4.86. Over the past 10 years, this metric has ranged from a low of 1.99 to a high of 6.91. The Medical Devices & Instruments industry median Current Ratio is 2.49. Maxigen Biotech's value of 3.21 is 28.9% above this industry median. Based on the distribution chart, Maxigen Biotech ranks #328 out of 855 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's Current Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Maxigen Biotech ranks #328 out of 855 companies for Current Ratio. This puts Maxigen Biotech in the upper half of its industry. The industry median Current Ratio is 2.49. Maxigen Biotech's value of 3.21 is 28.9% above this benchmark. Historically, Maxigen Biotech's own Current Ratio has ranged from 1.99 to 6.91 over the past decade. While the company's 10-year median is 4.86 vs. the industry median of 2.49, Maxigen Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Devices & Instruments company?
The median Current Ratio among Medical Devices & Instruments companies is 2.49, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Maxigen Biotech's current Current Ratio of 3.21 is 28.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median Current Ratio is 2.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Maxigen Biotech's current Current Ratio is 3.21, which is 34% below median its own 10-year median of 4.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$61.08, compared to a current price of NT$38.85 — trading 36.4% below its estimated fair value. The current Current Ratio is 3.21, which is 34% below median its 10-year median of 4.86 and 28.9% above the Medical Devices & Instruments industry median of 2.49. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current Current Ratio is 3.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Maxigen Biotech (TPE:1783) Overvalued in 2026?
Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued.
The current stock price of NT$38.85 is trading 36.4% below its estimated GF Value™ of NT$61.08.
GuruFocus considers Maxigen Biotech to be Significantly Undervalued.
Key valuation signals for TPE:1783:
Current Ratio: 3.21 (34% below median its 10-year median of 4.86)
GF Value™: NT$61.08 vs. price of NT$38.85 (36.4% below fair value)
Industry Position: 28.9% above the Medical Devices & Instruments median (#328 of 855)
No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score
Get the complete analysis for TPE:1783
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1783 has been successfully added to your 
